Galderma Group AG

GLP-1 Weight-Loss Boom Creates Tissue-Restoration Gap as Conexeu Advances Regenerative Platform Toward 2027 FDA Submission

- The GLP-1 drug market reached roughly $79 billion in 2025 and is projected to hit $190 billion by 2035, creating a surge in patients with facial and body volume loss that conventional injectables were not designed to address. - Galderma has presented interim clinical data validating the "Ozempic face" category, demonstrating its injectable portfolio can address medication-driven facial volume loss, while U.S. plastic surgeons saw over 837,000 GLP-1 patients in 2024. - Conexeu Sciences completed its P.R.O.O.F preclinical program for the CXU platform, a thermosensitive collagen scaffold designed for tissue regeneration rather than simple volumizing, with a 510(k) FDA submission targeted for Q1 2027. - The provider economy for GLP-1-related aesthetic concerns is projected to grow from roughly $0.7 billion in 2025 to $2.0 billion by 2030, within an $11 billion medical aesthetics injectable market.